Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine + Herceptin vs Capecitabine + Herceptin in Pretreated HER-2 Positive Metastatic Breast Cancer
NCT00440622Phase 3Terminated
- Sponsor
- Hellenic Oncology Research Group
- Start
- Apr 2003
- Primary completion
- Nov 2008
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of gemcitabine, capecitabine in breast cancer, sponsored by Hellenic Oncology Research Group. Started Apr 2003; status: terminated.
02
Drugs
gemcitabinecapecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00440622.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00440622.